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Background: Thyroid hormones have been shown to regulate breast cancer cells growth, the absence or reduction
of thyroid hormones in cells could provoke a proliferation arrest in G0-G1 or weak mitochondrial activity, which
makes cells insensitive to therapies for cancers through transforming into low metabolism status. This biological
phenomenon may help explain why treatment efficacy and prognosis vary among breast cancer patients having
hypothyroid, hyperthyroid and normal function. Nevertheless, the abnormal thyroid function in breast cancer
patients has been considered being mainly caused by thyroid diseases, few studied influence of chemotherapy on
thyroid function and whether its alteration during chemotherapy can influence the respose to chemotherapy is still
unclear. So, we aimed to find the alterations of thyroid function and non-thyroidal illness syndrome (NTIS)
prevalence druing chemotherapy in breast cancer patients, and investigate the influence of thyroid hormones on
chemotherapeutic efficacy.
Methods: Thyroid hormones and NTIS prevalence at initial diagnosis and during chemotherapy were analyzed in
685 breast diseases patients (369 breast cancer, 316 breast benign lesions). The influence of thyroid hormones on
chemotherapeutic efficacy was evaluated by chemosensitization test, to compare chemotherapeutic efficacy
between breast cancer cells with chemotherapeutics plus triiodothyronine (T3) and chemotherapeutics only.
Results: In breast cancer, NTIS prevalence at the initial diagnosis was higher and increased during chemotherapy,
but declined before the next chemotherapeutic course. Thyroid hormones decreased signigicantly during
chemotherapy. T3 can enhance the chemosensitivity of MCF-7 to 5-Fu and taxol, with progression from G0-G1
phase to S phase. The similar chemosensitization role of T3 were found in MDA-MB-231. We compared
chemotherapeutic efficacy among groups with different usage modes of T3, finding pretreatment with lower dose
of T3, using higher dose of T3 together with 5-Fu or during chemotherapy with 5-Fu were all available to achieve
chemosensitization, but pretreatment with lower dose of T3 until the end of chemotherapy may be a safer and
more efficient therapy.
Conclusions: Taken together, thyroid hormones decreasing during chemotherapy was found in lots of breast
cancer patients. On the other hand, thyroid hormones can enhance the chemotherapeutic efficacy through
gatherring tumor cells in actively proliferating stage, which may provide a new adjuvant therapy for breast cancer
in furture, especially for those have hypothyroidism during chemotherapy.
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Thyroid hormones, which function in cell development,
differentiation, growth, and other aspects of metabolism,
are regulated by hypothalamic-pituitary axis. In cancer
patients, thyroid function is thought to be vulnerable
to chemotherapy, as hypothalamic-pituitary axis is ac-
tive and chemotherapy is systemic therapy for patients.
The influence of chemotherapy on thyroid function
was just seen as a late effect [1,2], mainly presenting
hypothyroidism. Nevertheless, thyroid function de-
creasing does not occur in all cancer patients receiv-
ing chemotherapy, thyroxine (T4), T3 and reverse
triiodothyronine (rT3) levels of patients with non-
seminoma testicular carcinoma increased significantly
during chemotherapy [3], some choriocarcinoma pa-
tients even suffered thyroid crisis during chemother-
apy [4,5], the cause may be the high levels of human
chorionic gonadotrophin (HCG), producing biochem-
ical and clinical hyperthyroidism [6]. While, non-
seminoma testicular carcinoma and choriocarcinoma
are rare human malignancies that are highly curable
with chemotherapy or combination of surgery and
chemotherapy, even with widespread metastases. For
breast cancer patients, studies did not directly show
chemotherapy can influence thyroid function, only
found some results indicative hypothyroidism, such as
elevated concentrations of thyroid stimulating hor-
mone (TSH), thyroperoxidase antibody (anti-TPO),
thyroglobulin antibody (anti-Tg) [7] and decreased T3
uptake levels [8]. Few studied the alteration of thyroid
function in breast cancer patients during chemother-
apy, the time that chemotherapeutic reagents take
effect in.
On the other hand, chemotherapeutic efficacy can be
influenced by certain endocrine hormones or related
therapy. In vivo, rat treated with growth hormone and
chemotherapy had better efficacy than those treated with
chemotherapy only [9]. In clinic, tamoxifen, which com-
petitively combine with estrogen receptor, can not be
concurrently used with chemotherapy for breast cancer
patients, as the cancer growth inhibition by tamoxifen
makes tumor cells insensitive to chemotherapy. Interest-
ingly, choriocarcinoma and testicular carcinoma are
highly curable with chemotherapy, even with widespread
metastases, they have elevated thyroid hormones in
common during chemotherapy, is better chemothera-
peutic efficacy related with elevated thyroid hormones?
Whether T3 can enhance sensitivity of breast cancer
cells to chemotherapy is unclear.
In this study, 1698 serum samples in 685 cases of
breast diseases, including 369 cases of breast cancer and
316 cases of breast benign lesions were analyzed to study
the thyroid hormones and NTIS prevalence in breast can-
cer patients at initial diagnosis and during chemotherapy.According to the changes of thyroid hormones during
chemotherapy, the effect of T3 on sensitity of breast can-
cer cells to chemotherapy was studied.
Methods
Patients and samples
A total of 685 female patients with breast diseases ad-
mitted in the First Affiliated Hospital of Chongqing
Medical University, with median age of 49 years (range
17–81 years) was studied, including 316 cases of breast
benign lesions, such as fibroadenoma, mastopathy,
intraductal papilloma, lipoma, etc. and 369 cases of
breast carcinoma, among which 224 cases were initially
diagnosed with breast carcinoma. All breast diseases
were confirmed by the pathology. No history of thyroidal
diseases or liver, renal dysfunction was found in these
patients. All breast cancer patients were treated with
standard chemotherapy. A total of 1698 samples were
collected from all patients on the first admission and /
or 1 to 3 days before and / or 1 to 3 days after each cycle
chemotherapy.
Ethical approval for this study and agreement by all
patients were obtained from the Biomedicine Ethics
Committee of The First Affiliated Hospital of Chongqing
Medical University. Each subject signed an agreement of
participation in this study that was approved
by Biomedicine Ethics Committee of The First Affiliated
Hospital of Chongqing Medical University and con-
sented to publish. The protocol of the study adhered to
the tenets of the Declaration of Helsinki and was ap-
proved by the local ethics committee.
Thyroid function assay
T3, T4, free triiodothyronine (FT3), free thyroxine (FT4),
TSH were detected by UnicelTM DXI 800 with chemilu-
minescence methods in the Laboratory of Endocrinology
of the First Affiliated Hospital of Chongqing Medical
University.
Cell line and cell culture
The MCF-7, MDA-MB-231 breast cancer cell lines were
supported by Molecular Oncology and Epigenetics
Laboratory, the First Affiliated Hospital of Chongqing
Medical University. The cell lines were maintained in RPMI
1640 (Gibco-BRL, Karlsruhe, Germany) supplemented with
10% fetal bovine serum (FBS) (PAA Laboratories, Linz,
Austria), 100 U/ml penicillin and 100 mg/ml streptomycin,
at 37°C in a humidified atmosphere containing 5% CO2.
Chemosensitization test and reagents
The chemosensitization role of T3 (Sigma Aldrich, Italy)
is reflected by changes of sensitivity of breast cancer
cells to 5-fluorouracil (5-Fu) (Xu Dong, China) or Taxol
(De Bao, China). The concentration of T3 used for
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5-Fu and Taxol were used at the IC50 concentration for
each cell line (5-Fu: 13 μmol/L for MCF-7, 8 μmol/L for
MDA-MB-231; Taxol: 0.4 μmol/L for MCF-7, 0.5 μmol/L
for MDA-MB-231). According to different concentrations
of T3, the chemosensitization test comprised nine inde-
pendent tests, each contained eight groups with a specific
T3 concentration (Figure 1). Before chemosensitization
test began, the MCF-7 cells in logarithmic growth phase
were trypsinized and seeded at a density of 3000/well into
96-well plates at 37°C in 5% incubator. After 21 h, the
chemosensitization test began.
The 1st to 3rd groups were pretreated with T3 for 24
h, then treated with 5-Fu for 48 h, the depriving times of
T3 were different, the 1st group was kept with T3 until
test end, T3 of the 2nd group was deprived at the start
of 5-Fu, and T3 of the 3rd group was deprived after
using 5-Fu for 24 h.
After 24 h without T3 pretreatment, the 4th to 6th
groups were also treated with 5-Fu for 48 h. The 4th
group was added with T3 at the start of 5-Fu until test
end, T3 of the 5th group was added at the start of 5-Fu
and deprived after using for 24 h, T3 of the 6th group
was added when 5-Fu was added for 24 h.
After 24 h without T3 pretreatment , the 7th group
was treated with 5-Fu only for 48 h, and without treating
with T3. The 8th group was set as control group, without
treating with T3 or 5-Fu.
Cell proliferation assay and inhibition ratio calculation
Before cell proliferation assay, wells of all groups were
washed with PBS for two times, replaced with fresh
culture medium, and set one new group with culture
medium only as blank control. Cell counting kit-8
(CCK8) (Dojindo Laboratories, Japan) was used to
evaluate the viability of cells in all groups according toFigure 1 The illustration for chemosensitization test with different gr
treated with 5-Fu for 48 h, the depriving times of T3 were different, the 1st
deprived at the start of 5-Fu, and T3 of the 3rd group was deprived after u
groups were also treated with 5-Fu for 48 h. The 4th group was added wit
at the start of 5-Fu and deprived after using for 24 h, T3 of the 6th was add
pretreatment, the 7th group was treated with 5-Fu only for 48 h, and with
treating with T3 or 5-Fu.the instructions of the manufacturer. The final con-
centration used for assay was 10%, after incubation with
cells for 1 h at 37°C to allow CCK8 to form formazan
crystals by reacting with metabolical active cells, the
OD value was measured in a microplate reader at
450 nm. The inhibition ratio was calculated by following
formula: 1-OD value of treated group / OD value of
control group. All experiments were repeated at least
three times by same person.Flow cytometry analysis of cell cycle
Flow cytometry analysis of cell cycle was implemented
as previously reported [10]. For cell cycle analysis, cells
were fixed in ice-cold 70% ethanol and stained with
propidium iodide (PI). The cell cycle profiles were
assayed using the Elite ESP flow cytometry at 488 nm,
and the data were analyzed using the CELL Quest soft-
ware (BD Biosciences, San Jose, CA). Flow cytometric
analysis was immediately performed.
Statistical analysis
All statistical analyses were performed using SPSS 18.0
statistical software. The Student’s t-test was used to
compare thyroid function between patients of benign le-
sions and cancer, the comparison of thyroid function be-
tween postchemotherapy and prechemotherapy, thyroid
function between two consecutive prechemotherapies
were performed with paired statistical comparison, the
nonparametric test was used when equal variances is not
assumed. The Anova or the nonparametric tests were
applied to compare the proportion of tumor cells in S
phase between treated and control group, inhibition ra-
tios among seven different treated groups. Results of
thyroid functions were presented as mean ± SD, values
of P≤0.05 were considered significant.oup. The 1st to 3rd groups were pretreated with T3 for 24 h, then
group was kept with T3 until test end, T3 of the 2nd group was
sing 5-Fu for 24 h. After 24 h without T3 pretreatment, the 4th to 6th
h T3 at the start of 5-Fu until test end, T3 of the 5th group was added
ed when 5-Fu was added for 24 h. After 24 h without T3
out treating with T3. The 8th group was set as control group, without
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Thyroid function of patients with breast benign lesions
and breast cancer
A total of 224 serum samples of breast cancer patients and
316 samples of breast benign lesion patients at initial diag-
nosis were analyzed for thyroid hormones. Thirty-seven of
224 breast cancer patients were diagnosed as NTIS (either
FT3 or FT4 is below the normal), of which the morbidity
was higher than that in breast benign lesions patients
(16.5% vs 7.3%). The mean concentrations of T3, FT3
in breast cancer patients were lower than that in breast
benign lesions patients, however, only difference of T3 be-
tween them was statistically significant (P<0.05). On con-
trary, the mean concentrations of T4 and TSH were higher
in breast cancer patients, but only difference of T4 between
them was statistically significant (P≤0.05) (Table 1).
Alterations of thyroid function in breast cancer patients
during chemotherapy
Blood samples from 180 cases of breast cancer patients
were analyzed in this part. Eighty-two point two percent
(82.2%) patients suffered NTIS during chemotherapy. T3,
T4, FT3, TSH decreased and FT4 increased significantly
during chemotherapy compared with prechemotherapy
(P<0.05) (Table 2).Table 1 Comparison of thyroid function between patients of
(mean ± SD)








Clinicopathological features of breast cancer
Tumor size T0 (impalpable)
T1 (≤2 cm)












UnknownComparison of thyroid function between two consecutive
prechemotherapies
A total of 456 samples were analyzed between
two consecutive prechemotherapies, no significant differ-
ences of thyroid function were found (P>0.05) (Table 3).The chemosensitization test of triiodothyronine
The thyroid functions decreasing during chemotherapy in-
dicated adding thyroid hormones may enhance the sensitiv-
ity of tumor cells to chemotherapy, as T3 can induce cells
progression from G0-G1 phase to S phase [11] or enhance
mitochondrial activity [12] which makes tumor cells more
sensitive to chemotherapy. So, as the specific chemothera-
peutic reagent for killing tumor cells in S phase, 5-Fu was
choosed to study the change of sensitivity of breast cancer
cells when T3 was present. Three groups were set up, cells
were seeded in quintuplicate in 96-well plate at a density of
3×103 cells/well. The 1st group was treated with T3 and 5-
Fu, the 2nd group was treated with 5-Fu only, the 3rd
group was set as control group. We firstly used 4 ng/ml T3
to pretreat MCF-7 or MDA-MB-231 for 24 h, then 5-Fu
was added and T3 were deprived, values of OD after 48 h
were measured, the results showed that both MCF-7 and
MDA-MB-231 pretreated with T3 were more sensitive tobreast benign lesions and cancer on initial diagnosis






















Table 2 Comparison of thyroid function in breast cancer patients between prechemotherapy and postchemotherapy
(mean ± SD)
Thyroid function Prechemotherapy (n=180) Postchemotherapy (n=180) p value
T3 (ng/ml) 1.16±0.27 0.80±0.27 <0.001
T4 (μg/dl) 7.30±1.23 6.87±1.57 <0.001
FT3 (pg/ml) 2.89±0.57 2.10±0.49 <0.001
FT4 (ng/dl) 0.85±0.14 0.90±0.19 0.019
TSH (μIU/ml) 2.78±2.16 1.00±1.31 <0.001
Age (y) 49.8
Clinicopathological features Number
Tumor size T0 (impalpable) 7
T1 (≤2 cm) 66
T2 (>2 cm, ≤5 cm) 90
T3 (>5 cm) 12
Unknown 5














TEC: Docetaxel, Epirubicin, Cyclophosphamide.
CEF: Cyclophosphamide, Epirubicin, Fluorouracil.
NP: Navelbine, Cisplati.
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(P<0.05) (Figure 2A and 2B).
The 5-Fu especially targets tumor cells in S phase, to
study whether enhancement of sensitivity of tumor cells
to 5-Fu was related with increasing proportion of breast
cancer cells in S phase, we further investigated the effect
of T3 on MCF-7 cell cycle. Representative results of cell-
cycle distribution in MCF-7 pretreated with T3 or with-
out T3 were shown in Figure 2C. Flow cytometry analysis
revealed a statistically significant increase in the number
of T3 pretreated MCF-7 with S phase (P<0.05), accompan-
ied with the increase in G2-M phase and decrease in G0-
G1 phase (P<0.05) (Figure 2D). So, T3 enhanced the sensi-
tivity of MCF-7 to 5-Fu, through promoting the cell cycle
progression of MCF-7 from G0-G1 phase to S phase.
Besides discussing the effect of thyroid hormone on 5-Fu,
we also observed whether T3 has the chemosensitizationrole for Taxol. Taxol works differently by arresting the cells
in G2-M phase, considering a higher concentration of T3
may be more efficient in promoting breast cancer cells pro-
liferation, we used 24 ng/ml T3 to pretreat MCF-7 or
MDA-MB-231, the results showed that both MCF-7 and
MDA-MB-231 pretreated with T3 were more sensitive to
Taxol than those with Taxol only, without T3 pretreatment
(P<0.05) (Figure 2E and 2F).
The different usage modes of triiodothyronine on
chemosensitivity of MCF-7
Considering the thyroid function decrease during
chemotherapy, which may induce breast cancer cells re-
tardant in G0 phase, and T3 could enhance
chemosensitivity of MCF-7 through increasing propor-
tion of cells in S phase, we thought T3 may be used as a
new adjuvant therapy for breast cancer, and started to
Table 3 Comparison of thyroid function in breast cancer patients between two consecutive prechemotherapies (mean ± SD)
Thyroid function Previous prechemotherapy (n=228) Next prechemotherapy (n=228) p value
T3 (ng/ml) 1.14±0.23 1.18±0.25 0.083
T4 (μg/dl) 7.11±1.20 7.07±1.19 0.553
FT3 (pg/ml) 2.84±0.37 2.90±0.67 0.188
FT4 (ng/dl) 0.85±0.14 1.27±6.66 0.736
TSH (μIU/ml) 3.11±3.35 2.76±2.30 0.064
Age (y) 49.5
Clinicopathological features Number
Tumor size T0 (impalpable) 7
T1 (≤2 cm) 90
T2 (>2 cm, ≤5 cm) 113
T3 (>5 cm) 16
Unknown 2














TEC: Docetaxel, Epirubicin, Cyclophosphamide.
CEF: Cyclophosphamide, Epirubicin, Fluorouracil.
NP: Navelbine, Cisplatin.
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chemosensitivity of MCF-7.
Eight groups were set as described in methods. As
4 ng/ml T3 had been proved to have chemosensitization
role by us, we then firstly use 4 ng/ml with different usage
modes to study the efficacy of T3 on chemosensitivity of
MCF-7. Surprisingly, only sensitivity of MCF-7 to 5-Fu in
the first three groups pretreated with T3 significantly in-
creased (P<0.05), no chemosensitization was found in the
4th to 6th groups (Figure 3A).
Whether elevating the T3 dose can enhance the
chemosensitivity of MCF-7 in 4th to 6th groups, those
without T3 pretreatment, and decreasing T3 could
reduce the chemosensitivity in the 1st to 3rd groups,
those were pretreated with T3, were still unclear. So, we
performed eight other chemosensitization tests with T3
at 2 ng/ml, 8 ng/ml, 12 ng/ml, 16 ng/ml, 20 ng/ml, 24
ng/ml, 28 ng/ml, 32 ng/ml, using the concentrations ofT3 more than 4 ng/ml (8 ng/ml to 32 ng/ml) is to imi-
tate the hyperthyroidism in choriocarcinoma patients re-
ceiving chemotherapy. The results showed 2 ng/ml T3
was not efficient enough to enhance the chemosensitivity
of MCF-7 to 5-Fu in any group (P>0.05) (Figure 3B),
which indicated the suitable dose of T3 is essential point
for chemosensitization. On the contrary, the MCF-7 in
4th to 6th groups successively showed significantly in-
creased chemosensitivity, compared with that of 7th
group (P<0.05), as the T3 dose elevating from 8 ng/
ml to 32 ng/ml (Figure 3C).
Discussion
Abnormal thyroid function in breast cancer patients at
initial diagnosis
Many non-thyroidal illness may affect the thyoid func-
tion and induce NTIS [13], which is also called euthyr-






Figure 2 Pretreating MCF-7 or MDA-MB-231 with T3 enhanced the sensitivity of breast cancer cells to 5-Fu and Taxol. (A) After using
4 ng/ml T3 to pretreat MCF-7 for 24 h, the inhibition ratio was higher in MCF-7 pretreated with T3, compared with MCF-7 with 5-Fu only, without
T3 pretreatment, * P<0.05. (B) The inhibition ratio was higher in MDA-MB-231 pretreated with T3, compared with those with 5-Fu only, without T3
pretreatment, * P<0.05. (C&D) MCF-7 pretreated with T3 for 24 h showed significantly increased proportion of cells in S phase, and significantly
decreased proportion of cells in G0-G1 phase, both compared with those of MCF-7 without T3 pretreatment, * P<0.05. (E&F) After using 24 ng/ml
T3 to pretreat MCF-7 or MDA-MB-231 for 24 h, the inhibition ratio was higher in cancer cells pretreated with T3, compared with those with Taxol
only, without T3 pretreatment, * P<0.05.
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peripheral conversion of T4 to T3, presumed to reflect a
homeostatic mechanism to conserve energy. TSH levels
tend to be normal or slightly decreased in these patients,
but the underlying mechanism of reduced thyroid func-
tion is unknown. In this study, the NTIS prevalence in
breast cancer patients at initial diagnosis was higher
than that in breast benign lesions patients (16.5% vs
7.3%). The high NTIS prevalence in breast cancer pa-
tients at initial diagnosis suggests that NTIS may be
related with malignancy. Furthermore, it was found in
this study that the mean concentration of FT3 in
breast cancer patients at initial diagnosis was signifi-
cantly lower than that in breast benign lesions pa-
tients, suggesting that thyroid hypofunction mayoccur in breast cancer patients. Galton VA [16] stud-
ied the effect of malignant tumor on the thyroid
function in rats, implanted with Walker 256 carcino-
sarcoma cell line, results showed a reduction in the
concentration of T4 in tumorous rats serum, com-
pared with corresponding control rats, due to the in-
creased deiodination and urinary excretion.
The causes for hypothyroidism in cancer patient
may not only be associated with tumor necrosis fac-
tor, interleukin-1, interferon-γ [17,18], which inhibits
the function of hypothalamus-pituitary-thyroid axis
and peripheral conversion of T4 to T3, but also be
associated with the self-protection mechanism, redu-
cing the tissue metabolism to suppress the tumor
growth.
Figure 3 The effect of different usage modes of T3 on sensitivity of MCF-7 to 5-Fu. (A) Only sensitivity of MCF-7 to 5-Fu in the 1st to 3rd
groups pretreated with 4 ng/ml T3 significantly increased, compared with that in group treated with 5-Fu only (7th group), * P<0.05; No
significant difference of inhibition ratio was found between each of the 4th to 6th groups and 7th group, * P>0.05. (B) Pretreament MCF-7 with
2 ng/ml T3 did not show significant difference of inhibition ratio between each of 1st to 6th groups and 7th group, * P>0.05. (C) The inhibition
ratio of different usage modes of T3, which ranged from 8 ng/ml to 32 ng/ml. The sensitivity of MCF-7 to 5-Fu in the 1st to 3rd groups
pretreated with T3 all significantly increased, * P<0.05; The MCF-7 in 4th to 6th groups successively showed significantly increased
chemosensitivity, compared with that of 7th group, * P<0.05, as the T3 dose elevating from 8 ng/ml to 32 ng/ml.
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during chemotherapy
Chemotherapy is one of the most effective systemic
therapies for cancers. In cancer patients, thyroid func-
tion is thought to be vulnerable to chemotherapy, as
hypothalamic-pituitary axis is active and chemother-
apy is systemic therapy for patients. The influence of
chemotherapy on thyroid function was just seen as a
late effect, mainly presenting hypothyroidism. Only
few studied the alterations of thyroid function during
chemotherapy, which induced abnormalities in thyroid
hormones metabolism with a significant decrease in
serum T3 concentration (NTIS) instead of overt thy-
roid disease in malignant hematologic disease [19].
Thyroid hypofunction was thought to be associated
with inhibition of the liver thyroglobulin secretion
[20] and hypothalamus-pituitary-thyroid axis function
[7] by chemotherapy.
In this study, NTIS prevalence in breast cancer pa-
tients obviously increased during chemotherapy, com-
pared with that at initial diagnosis (87.1% vs 16.5%) and
then decreased to 15.4% before the next chemotherapy
(prechemotherapy). The NTIS prevalence reduction
from 16.5% to 15.4% indicated that chemotherapy allevi-
ated the NTIS prevalence, as thyroid hypofunction is
considered as risk for breast cancer occurrence [21]
and poor prognosis [22], this also suggests that NTIS
alleviation may be a good efficacy by chemotherapy.
With significantly increased NTIS prevalence duringchemotherapy, whether controlling it is better for en-
hancing chemotherapeutic efficacy is unclear.
Furthermore, during chemotherapy for breast cancer
patients in this study, significant decreases of T3, T4, FT3
and TSH were found, compared with prechemotherapy
(P<0.05). After chemotherapy, thyroid function began to
recover, and there was no significant difference between
two consecutive prechemotherapies (P>0.05), which in-
dicated obvious thyroid function decreasing caused by
chemotherapy mainly occurred during chemotherapy.
While there is still no detailed study on whether de-
crease of thyroid function goes against breast cancer
chemotherapy or not. Decrease of thyroid function does
not occur in all patients with malignant tumors during
chemotherapy. In a prospective study, effects of chemo-
therapy on thyroid function in patients with non-
seminoma testicular carcinoma were evaluted: Serum
HCG was present in sixteen patients and absent in fif-
teen. HCG levels ranged from 10 to 30,000 μg/l, with a
median value of 520 μg/l. And during chemotherapy,
T4, T3 and rT3 levels increased significantly, but basal
TSH levels and the TSH response to thyrotropin re-
leasing hormone (TRH) decreased. Furthermore, after
chemotherapy the increased T4 and lowered TSH
levels returned to normal, while the FT3 level did not
change either during or after chemotherapy [3], which
suggested an unaltered hypothalamic / pituitary axis.
Non-seminomatous germ-cell tumors (NSGCT) can com-
prise several different histological components, among
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tients with high-serum HCG levels, hyperthyoidism has
been recognized and is considered to be a paraneoplastic
phenomenon. Hyperthyroidism frequently accompanies
NSGCT with highly elevated HCG [23]. Recent investiga-
tions have clarified the structural homology not only
in the HCG and TSH molecules but also in their re-
ceptors, and this homology suggests the basis for
the reactivity of HCG with the TSH receptor [24,25].
Hyperthyroidism or increased thyroid function has
been reported in many patients with trophoblastic tu-
mors [26], either hydatidiform mole [27,28] or chorio-
carcinoma [25], for which the principal therapy is
chemotherapy. With effective chemotherapy, their long
term survival exceeds 95% [24,29]. Furthermore,
hyperthyroidism can be cured after the healing of the
trophoblastic tumors [30]. Meister LH et al. reported a
26-year-old pregnant woman suffered from choriocar-
cinoma with metastases to both lungs. HCG were more
than 2.5×106 mU/ml. Consistent with HCG-induced
hyperthyroidism, the patient suffered from thyroid
crisis with fever of 38.6°C, worsening respiratory dis-
tress, tachycardia of 140 bpm and mental confusion
during the first cycle of chemotherapy. Then the pa-
tient was treated with antithyroid crisis, symptomatic
and supportive treatments. After the 10th cycle of
chemotherapy the patient was in good condition and
free of metastatic lesions in her chest X-ray [5]. It was
reported that thyroid hormones could significantly
promote the tumor growth and metastases [31]. The
effective chemotherapy of curable tumors (such as ma-
lignant hydatidiform mole, choriocarcinoma, etc.) may
be associated with hyperthyroidism during chemother-
apy, which may enhance the chemotherapeutic sensi-
tivity by inducing tumor cells progression from G0-
G1 phase into S phase or elevating the mitochondrial
activity. While, in this study, thyroid function de-
creased significantly and majority of the breast cancer
patients suffered NTIS during chemotherapy, which
may be associated with decreased chemotherapy sen-
sitivity. Therefore, based on the above analysis, it was
hypothesized that increasing the thyroid function by
giving thyroid hormones before and / or during chemo-
therapy to imitate the hyperthyroidism or high thyroid
function state of some choriocarcinoma patients during
chemotherapy may enhance the chemotherapeutic efficacy
in breast cancer and other malignant tumor patients who
suffer obviously decreased thyroid function or NTIS dur-
ing chemotherapy.Effect of triiodothyronine on chemosensitization
The effect of thyroid hormones on chemotherapeutic ef-
ficacy has been rarely researched before, and whetheradding thyroid hormones during chemotherapy is suit-
able for breast cancer patients is still unknown. Some
studies found hypothyroidism may be the protective fac-
tor for cancers, as hypothyroidism can suppress tumor
growth [32], in addition, Hercbergs et al. found that
hypothyroidism could reduce the insulin-like growth fac-
tor 1, the antagonist of tamoxifen-induced cytotoxicity,
to prolong the survival in recurrent high grade glioma
patients [33]. This above mentioned perspective is differ-
ent from our hypotheses, since we think hyperthyroid
function is beneficial for treatment efficacy when pa-
tients receive chemotherapy. If patients of cancers
reveive no chemotherapy, the status of hypothyroidism
will be better for prognosis. Choriocarcinoma is curable
with chemotherapy only, long term survival of these
patients exceeds 95%, the underlying mechanism may
refer with high levels of HCG, which can induce hyper-
thyroidism [6]. In contrast, we firstly found thyroid
hormones decreasing and NTIS prevalence increasing
during chemotherapy in breast cancer patients, however,
growth of breast cancer cells is regulated by thyroid hor-
mones [34], thyroid hormones are considered to be
the growth factor for glioma and thyroid cancer [35],
the absence of thyroid hormones in cells could pro-
voke a proliferation arrest in G0-G1 [36] or weak
mitochondrial activity [12], which makes tumor cells
insensitive to chemotherapy.
Basing on these points, we performed T3 chemo-
sensitization test in breast cancer cells. The normal FT3
concentration in human body is 2.2-4.2 ng/ml, we take
the physiological concentration range of FT3 as the refer-
ence standard. Therefore, 4 ng/ml T3 was used firstly in
cell culture medium which contains no thyroid hormones,
to evaluate whether the physiological concentration of T3
can elevate the chemotherapeutic efficacy. 5-Fu, the che-
motherapeutic regent mainly focusing on tumor cells in S
phase, is a usual component in chemotherapy for breast
cancer. The T3 pretreatment induced MCF-7 increased
progression from G0-G1 phase to S phase, with elevated
chemosensitivity to 5-Fu, the similar result was found in
MDA-MB-231. Taxol works differently by arresting the
breast cancer cells in G2-M phase, it enhances the
polymerization of tubulin to stable microtubules and also
interacts directly with microtubules, stabilizing them
against depolymerization by cold and calcium, which read-
ily depolymerize normal microtubules, so cells treated with
taxol are unable to form a normal mitotic apparatus. To
prove T3 can sensitize the breast cancer cells to Taxol, we
used 24 ng/ml T3 to pretreat MCF-7 or MDA-MB-231, the
results showed that both MCF-7 and MDA-MB-231
pretreated with T3 were more sensitive to Taxol than those
with Taxol only, without T3 pretreatment.
Both MCF-7 and MDA-MB-231 express the thyroid
hormone receptor, the chemosensitization role of T3 in
Thyroid hormone
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Figure 4 Possible mechanism of choriocarcinoma chemotherapy and chemosensitization role of thyroid hormone in breast cancer.
Choriocarcinoma has better chemotherapeutic efficacy, the possible cause may be related with high HCG releasing when most choriocarcinoma
cells (CC) are killed by chemotherapy, besides those stay in low metabolism level, which permits them from cytotoxicity effect on some level.
As HCG has TSH like effect, thyroid hormone increases and promotes CC retardant in G0 phase stepping into cell division cycle, which makes CC
more sensitive to chemotherapy. However, in breast cancer, thyroid hormone decreasing occurs in most breast cancer patients when
chemotherapy is applied, but there is no spontaneous complement of thyroid hormone in microenviroment of breast cancer cells (BC). The
absence or lack of thyroid hormone may induce G0 arrest, which makes residual BC insensitive to subsequent chemotherapy. So, inexistence of
thyroid hormone decreasing in choriocarcinoma, even thyroid hormone increasing during chemotherapy, inspires us to imitate this thyroid
hormone changing model in breast cancer. As we expect, the chemosensitivity can be enhanced by adding thyroid hormone before and / or
during chemotherapy, which is elaborately illustrated in our cell based experiment.
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liferation efficacy of T3. In MCF-7, an estrogen receptor
positive breast cancer cell line, the proliferative effect of
thyroid hormone is not only initiated through the com-
bination with the thyroid hormone receptor, but also
through the combination with the estrogen receptor
[37]. There are specific mechanisms that explain why
thyroid hormone stimulate cell proliferation in gastric
cancer cells, the cyclin/cyclin-dependent kinase levels
and activity are involved [11]. Dinda et al. [38] found
thyroid hormone not only enhances the phosphorylation
of pRb, but also induces the c-Myc expression and mu-
tant P53 expression, this can also explain the cell prolif-
eration efficacy of thyroid hormone. MDA-MB-231 is
acknowledged harboring P53 mutations, which furtherdemonstrates that thyroid hormone may promote the
cell proliferation. Furthermore, thyroid hormone was
found to sensitize the mitochondrial pathway to enhance
the chemotherapeutic efficacy in MDA-MB-231 [12].
Thyroid hormone exerts its non-genomic and genomic
actions in breast cancer cells [12]. For non-genomic ac-
tion, which is characterized by combination of thyroid
hormone and membrane receptors such as ER to eluci-
date the downstream signaling cascade, and is independ-
ent of transcriptional activity [39]. For genomic action,
thyroid hormone primary mode is by binding to the thy-
roid hormone receptor in the nucleus then influencing
the transcription and expression patterns of target genes.
In MCF-7, which expresses ER and thyroid receptor, the
chemosensitization role of T3 is mediated through the
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MB-231, which expresses thyroid receptor, the enhanced
chemotherapeutic efficacy can also be contributed to the
genomic and non-genomic actions of T3, like the influ-
ence on genes expression and the elevated mitochondrial
activity mentioned above.
In light of the findings mentioned above, T3 may be
used as adjuvant therapy for breast cancer patients in
the future, the main points for its application are usage
dose and how to combine it with chemotherapy. To imi-
tate different usage modes of T3 in clinic, six individual
groups with treatment by T3 and 5-Fu were set up to
separately compare with control group treated with 5-Fu
only. It is indicated in this results that, to get che-
mosensitization efficacy, pretreatment with lower dose
of T3, using higher dose of T3 together with 5-Fu or dur-
ing chemotherapy with 5-Fu were all thought to be avail-
able. In clinic, however, using higher dose of T3 will
increase the risk of suffering thyroid crisis, and in
most of T3 chemosensitization tests from 4 ng/ml to
32 ng/ml, the relative inhibition ratio in 1st group was
highest, except T3 at 16 ng/ml and 24 ng/ml. So, pre-
treatment with lower dose of T3 until the end of chemo-
therapy may be a safer and more efficient therapy for
breast cancer patients. In addition, only a suitable dose
of T3 could have chemosensitization role in chemother-
apy, treatment with extremely low dose of T3 for long
time (72 h) still could not enhance the chemosensitivity
of MCF-7 to 5-Fu.
Using T3 for chemosensitization in breast cancer ther-
apy is to simulate the high thyroid function in choriocar-
cinoma patients during chemotherapy, based on the
new findings that thyroid hormones decreasing during
chemotherapy, in which chemotherapeutic regents mainly
take effect.
In summary, we studied the thyroid hormones and
NTIS in breast patients at initial diagnosis and during
chemotherapy, in which with a thyroid function signifi-
cant decreasing, and found T3 enhanced the chemo-
sensitivity of MCF-7 to 5-Fu. Moreover, we think the
chemotherapeutic efficacy partly depends on the thyroid
function, checking the thyroid function in breast cancer
patients is important for elevating chemotherapeutic
efficacy.
Conclusion
Therefore, it was hypothesized, in this article, that
through imitating the high thyroid function or high
endocrine hormone state of some choriocarcinoma
patients during chemotherapy, the chemosensitivity may
be enhanced by giving thyroid hormones or other endo-
crine hormones to the patient before and / or during
chemotherapy, which may bring a new therapy to breast
cancer and other malignant tumors. This new therapy,extremely different from the traditional concept of
endocrinochemotherapy (i.e., chemotherapy plus endo-
crinotherapy), might be termed as hormono-sensitizing
chemotherapy (HSCT), endocrinosensitizing chemothe-
rapy (ESCT), or neo-endocrinochemotherapy (NECT).
The detailed mechanisms are included in Figure 4 [40].
If the hypothesis mentioned above proves to be clinically
safe and feasible, NECT might replace the current
chemotherapy in future.
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